Healthcare - Biotechnology - NASDAQ - US
$ 0.9915
-1.83 %
$ 41.1 M
Market Cap
-0.63
P/E
CASH FLOW STATEMENT
-60.3 M
OPERATING CASH FLOW
27.7 M
INVESTING CASH FLOW
143 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Rallybio Corporation
| Net Income | -74.6 M |
| Depreciation & Amortization | 150 K |
| Capital Expenditures | -12 K |
| Stock-Based Compensation | 10.9 M |
| Change in Working Capital | 4.28 M |
| Others | 3.33 M |
| Free Cash Flow | -60.3 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (74.6) | (66.7) | (47.0) | (26.4) | (17.6) |
| Depreciation & Amortization | 0.1 | 0.2 | 0.1 | 62 K | 26 K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0.1 |
| Stock Based Compensation | 10.9 | 9.5 | 3.6 | 0.7 | 0.2 |
| Other Operating Activities | (1.0) | 0.6 | 1.5 | 1.5 | 0.1 |
| Change in Working Capital | 4.3 | (0.9) | (3.8) | 2.1 | 2.1 |
| Cash From Operations | (60.3) | (57.3) | (45.5) | (22.0) | (15.0) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 12 K | 54 K | (0.3) | (0.1) | (0.2) |
| Other Items | 27.7 | (112.1) | (2.0) | (1.9) | 0 |
| Cash From Investing Activities | 27.7 | (112.2) | (2.3) | (2.1) | (0.2) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0.3 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.1 | (0.5) | (3.2) | (0.3) | 33 K |
| Cash From Financing Activities | 0.1 | 51.1 | 83.0 | 144.9 | 31.6 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (32.5) | (118.4) | 35.1 | 120.8 | 16.4 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (60.3) | (57.3) | (45.9) | (22.2) | (15.2) |